We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
101
Neurocrine Biosciences
NBIX
$18.4B
$624K 0.26%
6,512
+1,421
+28% +$137K
HALO icon
102
Halozyme
HALO
$9.9B
$621K 0.26%
14,543
-11,069
-43% -$398K
GBT
103
DELISTED
Global Blood Therapeutics, Inc.
GBT
$617K 0.26%
14,254
+4,926
+53% +$243K
FSK icon
104
FS KKR Capital
FSK
$3.08B
$615K 0.26%
37,145
-10,488
-22% -$174K
SRPT icon
105
Sarepta Therapeutics
SRPT
$1.63B
$612K 0.25%
3,590
-89
-2% -$13.2K
VNDA icon
106
Vanda Pharmaceuticals
VNDA
$310M
$612K 0.25%
46,602
-8,175
-15% -$98.4K
AMGN icon
107
Amgen
AMGN
$212B
$610K 0.25%
2,652
-31
-1% -$7.15K
INCY icon
108
Incyte
INCY
$26B
$610K 0.25%
7,011
+663
+10% +$57.4K
DCPH
109
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$610K 0.25%
10,681
+5,003
+88% +$297K
BIIB icon
110
Biogen
BIIB
$30.4B
$608K 0.25%
2,482
+389
+19% +$100K
ALXN
111
DELISTED
Alexion Pharmaceuticals
ALXN
$608K 0.25%
3,894
-1,453
-27% -$187K
KPTI icon
112
Karyopharm Therapeutics
KPTI
$161M
$605K 0.25%
2,606
+273
+12% +$63.3K
ENTA icon
113
Enanta Pharmaceuticals
ENTA
$367M
$603K 0.25%
14,321
+2,275
+19% +$100K
BHVN
114
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$600K 0.25%
6,997
+2,326
+50% +$197K
XLRN
115
DELISTED
Acceleron Pharma
XLRN
$599K 0.25%
4,681
-1,448
-24% -$170K
ALNY icon
116
Alnylam Pharmaceuticals
ALNY
$38.5B
$596K 0.25%
4,587
-75
-2% -$10K
LGND icon
117
Ligand Pharmaceuticals
LGND
$5.94B
$595K 0.25%
9,584
+1,002
+12% +$57.1K
EXEL icon
118
Exelixis
EXEL
$14.2B
$594K 0.25%
29,602
+3,498
+13% +$73.2K
GILD icon
119
Gilead Sciences
GILD
$167B
$593K 0.25%
10,171
+2,179
+27% +$131K
FOLD
120
DELISTED
Amicus Therapeutics
FOLD
$588K 0.24%
25,487
-27,987
-52% -$572K
NKTR icon
121
Nektar Therapeutics
NKTR
$2.39B
$587K 0.24%
2,300
+398
+21% +$103K
REGN icon
122
Regeneron Pharmaceuticals
REGN
$72.9B
$587K 0.24%
1,216
+222
+22% +$120K
MFIC icon
123
MidCap Financial Investment
MFIC
$811M
$583K 0.24%
54,894
-28,598
-34% -$278K
BPMC
124
DELISTED
Blueprint Medicines
BPMC
$582K 0.24%
5,188
-3,174
-38% -$334K
YMAB
125
DELISTED
Y-mAbs Therapeutics
YMAB
$577K 0.24%
11,662
+4,353
+60% +$201K
3 4
5
6 7

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.